LentiStable™

Manufacturing large quantities of lentiviral vector (LV) for late-phase clinical trials and product commercialization remains a challenge with the commonly used transient transfection process.

Stable cell line production of LV is the best option for manufacturing as this reduces production costs and increases the overall safety and reproducibility in gene therapy.

Our LentiStable™ Solution

We have generated suspension and adherent-based stable packaging and producer cell lines using an inducible system. Packaging cell lines stably integrate some of the components of the lentiviral system (Envelope, Gag/Pol and Rev, if required) into the cell genome. Producer cell lines integrate all components (Envelope, Gag/Pol, Rev and lentiviral vector genome) into the cell genome.